Formulations of guanylate cyclase C agonists and methods of use
US9925231B2 · kind B2 · utility
0Cited by
38References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 23, 2017 |
| Grant date | Mar 27, 2018 |
| Priority date | — |
| Expiry date | Mar 23, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y406/01002
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides low-dose formulations of guanylate cyclase-C (“GCC”) agonist peptides and methods for their use. The formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.